Market Overview

XTL Biopharma Buys Stake in Proteologics from Teva

Share:
Related TEVA
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks
Have You Heard About This Generic EpiPen Maker?
Mylan To Launch Its Own EpiPen Generic Rival At Half Price (Investor's Business Daily)

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva's shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Posted-In: News Asset Sales

 

Related Articles (TEVA)

View Comments and Join the Discussion!